Darwin AG (ISIN DE000A3C35W0), a European healthcare company specializing in human genetics and personalized products, announced it will participate in two capital markets conferences in spring 2026: the Invest conference in Stuttgart and the Equity Forum (German Spring Conference 2026) in Frankfurt. At both events, members of the management team will present the company's equity story, recent developments, and be available for one-on-one meetings.
The Invest conference, described as the leading expo for finance and investment, will take place from April 17 to 18, 2026, at Messe Stuttgart. Targeted at retail investors, it covers a broad range of investment types. Dr. Daniel Wallerstorfer, CEO of Darwin AG, will present on April 17 at 5:30 p.m. under the theme "Invest in the Future of Precision Health." He will provide insights into how personalized solutions are shaping tomorrow's healthcare market. Interested visitors can meet Darwin AG management in Hall 4, Booth 4E32, to learn about personalized health and the company's products. More information about Invest can be found here.
The Equity Forum's 2026 Spring Conference will be held from May 11 to 12, 2026, at the Flemings Selection Hotel in Frankfurt. This MiFID II-compliant professional event targets institutional investors, financial analysts, venture capital, and private equity investors. Darwin AG will present a corporate update and audited financial results for 2025, along with an operational and strategic outlook. The 2025 consolidated financial statements will be published in the Annual Report on May 12, 2026. The presentation is scheduled for May 12 from 9:20 a.m. to 9:55 a.m., followed by one-on-one meetings with Dr. Wallerstorfer. Individual meetings can be scheduled via the event tool on the conference website. More information about the 2026 German Spring Conference can be found here.
Darwin AG, headquartered in Munich, Germany, is a European healthcare company active in human genetics and the development of personalized products based on genetic analysis. Its genetic analyses are used in diagnosis, treatment, and prevention of diseases, as well as in producing individually tailored nutritional supplements and cosmetics. Darwin partners with physicians, therapists, pharmacists, nutritionists, and fitness trainers to optimize treatment and support based on genetic predispositions. The company also holds investments in innovative biotech, healthcare, and life sciences firms. More information is available at https://darwin-biotech.com/.
These conference appearances underscore Darwin AG's commitment to communicating its precision health strategy to both retail and institutional investors, potentially increasing visibility and attracting investment as the company continues to expand its personalized healthcare offerings.
